Drixoral is no longer available in the United States. The original formula, a 12-hour cold and allergy tablet, disappeared from store shelves in the early 2010s and was formally added to the FDA’s Discontinued Drug Product List in 2014. The FDA confirmed that Drixoral was not pulled for safety or effectiveness concerns, meaning the decision to stop manufacturing it was a business one, not a medical one.
Why Drixoral Disappeared
Drixoral was originally made by Schering-Plough, which listed it among its cold and decongestant brands alongside Afrin and Chlor-Trimeton. Each extended-release tablet contained two active ingredients: an antihistamine (dexbrompheniramine maleate, 6 mg) and a decongestant (pseudoephedrine sulfate, 120 mg). That combination made it effective for both a runny nose and sinus congestion in a single pill.
The product’s disappearance likely traces back to two factors. First, pseudoephedrine became increasingly regulated in the mid-2000s because it can be used to manufacture methamphetamine. Federal law moved pseudoephedrine products behind the pharmacy counter, imposed monthly purchase limits, and required photo ID and purchase tracking. Some states went further and required a prescription. These restrictions made pseudoephedrine-based products harder to sell in volume. Second, Schering-Plough went through a merger with Merck in 2009, and brand portfolio decisions during corporate mergers often lead to smaller products being dropped.
Is It Available in Canada?
A product called Drixoral Decongestant Nasal Spray is still listed as “marketed” in Canada’s drug product database under Bayer. However, this is a nasal spray containing oxymetazoline, a completely different active ingredient from the original Drixoral tablet. It is not the same product that loyal Drixoral users in the U.S. remember. The classic oral tablet formula does not appear to be actively sold in Canada either.
Finding the Same Active Ingredients
The exact combination in Drixoral (dexbrompheniramine plus pseudoephedrine in extended-release form) has been manufactured in generic form. The FDA has approved a generic version made by KVK-Tech containing the same 6 mg/120 mg extended-release formulation. Whether this generic is currently stocked at pharmacies varies, and availability has been inconsistent over the years. Your best bet is to call a local pharmacy and ask if they can order dexbrompheniramine maleate and pseudoephedrine sulfate extended-release tablets.
Because the product contains pseudoephedrine, you won’t find it on an open shelf even if a pharmacy carries it. You’ll need to ask at the pharmacy counter, show a photo ID, and sign a purchase log. In a handful of states, you may need a prescription.
OTC Alternatives That Come Close
If you can’t find the exact generic, no other product on the market perfectly replicates Drixoral’s formula. Dexbrompheniramine is an unusually potent antihistamine that isn’t widely used in other brands. But you can approximate the effect with two separate ingredients:
- For the antihistamine component: Brompheniramine (found in Dimetapp) is the closest relative to dexbrompheniramine. Chlorpheniramine (found in Chlor-Trimeton) is another older-generation antihistamine with a similar sedating profile.
- For the decongestant component: Pseudoephedrine is still available behind the pharmacy counter under brand names like Sudafed (the original, not Sudafed PE, which contains a different decongestant). Some combination products pair brompheniramine or chlorpheniramine with pseudoephedrine.
Keep in mind that older-generation antihistamines like brompheniramine and chlorpheniramine cause drowsiness, just as the original Drixoral did. That was part of the product’s profile. Newer antihistamines like loratadine or cetirizine don’t cause as much sedation but also work through a slightly different mechanism and won’t feel identical to what Drixoral delivered.
Why People Still Search for It
Drixoral developed a devoted following because its specific combination worked well for people with both allergy symptoms and congestion, and the extended-release format meant taking just one tablet every 12 hours. Many users found it more effective than the alternatives that replaced it on shelves. Online forums and petition sites have kept the conversation alive for over a decade, with former users regularly asking whether the product will ever return. As of now, neither the brand owner nor any manufacturer has announced plans to bring Drixoral back to the U.S. market.